What Happened to Lineage-and Leukemia-Specific Antigens? Implications for Therapeutic Use of Monoclonal Antibodies

  • J. H. Kersey
  • T. W. LeBien


The development of hybridoma and monoclonal antibody technology by Köhler and Milstein in 1975 [1] was certainly a major scientific event, without which the current workshop would not be held. Great expectations were clearly aroused in the immunologic and hematologic communities as a result of this technology. Specifically, the high expectations were related to the use of these antibodies in several areas, three of which we will discuss. In this report we hope to briefly review progress in the areas of (a) lineage-specific differentiation antigens, (b) leukemia-specific antigens, and (c) therapeutic use of monoclonal antibodies. Since the organizers of this meeting have requested that this be in the form of an editorial, we will attempt to conform.


Cell Surface Molecule Autologous Bone Marrow Transplantation Leukemia Associate Antigen Common Acute Lymphoblastic Leukemia Antigen Current Workshop 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Köhler G, Milstein G (1975) Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 256: 495–497PubMedCrossRefGoogle Scholar
  2. 2.
    Carroll L (1960) The annotated Alice. Bramhall, New York p 264Google Scholar
  3. 3.
    Abramson C, Kersey J, LeBien T (1981) A monoclonal antibody (BA-1) primarily reactive with cells of human B lymphocyte lineage. J Immunol 126: 83–88PubMedGoogle Scholar
  4. 4.
    Platt JL, LeBien TW, Michael AF (1983) Stages of renal ontogenesis identified by monoclonal antibodies reactive with lymphohemopoietic differentiation antigens. J Exp Med (in press)Google Scholar
  5. 5.
    Stashenko P, Nadler LM, Hardy R, Schlossman SF (1980) Characterization of a human B lymphocyte specific antigen. J Immunol 125: 1678–1685PubMedGoogle Scholar
  6. 6.
    Brooks PA, Beckman I, Bradley J, McNamara PJ, Thomas ME, Zola H (1980) Human lymphocyte markers defined by antibodies derived from somatic cell hybrids. I. A hybridoma secreting antibody against a marker specific for human B lymphocytes. Clin Exp Immunol 39: 477–485PubMedGoogle Scholar
  7. 7.
    Kersey JH, LeBien TW, Abramson CS, Newman R, Sutherland R, Greaves M (1981) p24: A human hemopoietic progenitor and acute lymphoblastic leukemia-associated cell surface structure identified with monoclonal antibody. J Exp Med 153: 726–731PubMedCrossRefGoogle Scholar
  8. 8.
    Melink GB, LeBien TW (to be published) Construction of an antigenic map for human B cell precursors. J Clin ImmunolGoogle Scholar
  9. 9.
    Neudorf SML, Boue DR, LeBien TW, Kersey JH (to be published) The common acute lymphoblastic leukemia antigen may define recent migrants to the human thymus. Exp. HematolGoogle Scholar
  10. 10.
    Jones NH, Borowitz MJ, Metzgar RS (1982) Characterization and distribution of a 24000-dalton antigen defined by a monoclonal antibody (DU-ALL-1) elicited to common acute lymphoblastic leukemia (cALL) cells. Leuk Res 2: 449–464CrossRefGoogle Scholar
  11. 11.
    Newman RA, Sutherland DR, LeBien TW, Kersey JH, Greaves MF (1982) Biochemical characterization of leukemia associated antigen p24 defined by the monoclonal antibody BA-2. Biochim Biophys Acta 701: 318–327PubMedCrossRefGoogle Scholar
  12. 12.
    Hercend T, Nadler LM, Pesando JM, Reinherz EL, Schlossman SF, Ritz J (1981) Expression of a 26000-dalton glycoprotein on activited human T cells. Cell Immunol 64: 192–196PubMedCrossRefGoogle Scholar
  13. 13.
    Brooks DA, Bradley J, Zola H (1982) A differentiation antigen expressed selectively by a proportion of human blood cells: Detection with a monoclonal antibody. Pathology 14: 5–11PubMedCrossRefGoogle Scholar
  14. 14.
    Greaves M, Delia D, Janossy G, Rapson N, Chessels J, Woods M, Prentice G (1980) Acute lymphoblastic leukemia associated antigen. IV. Expression on non-leukemic lymphoid cells. Leuk Res 4: 15–32PubMedCrossRefGoogle Scholar
  15. 15.
    Metzgar RS, Borowitz MJ, Jones NH, Dowell BL (1981) Distribution of common acute lymphoblastic leukemia antigen in nonhematopoietic tissues. J Exp Med 154: 1249–1254PubMedCrossRefGoogle Scholar
  16. 16.
    Lane DL, Koprowski H (1982) Molecular recognition and the future of monoclonal antibodies. Nature 296: 200–202PubMedCrossRefGoogle Scholar
  17. 17.
    Ritz J, Schlossman SF (1982) Utilization of monoclonal antibodies in the treatment of leukemia and lymphoma. Blood 59: 1–11PubMedGoogle Scholar
  18. 18.
    Filipovich AH, MGeave P, Ramsay NKC, Goldstein G, Mersey JH (1982) Pretreatment of donor bone marrow with monoclonal antibodies for prevention of acute graft versus host disease in allogeneic histocompatible bone marrow transplantation. Lancet 1: 1266–1269PubMedCrossRefGoogle Scholar
  19. 19.
    Le Bien TW, Ash RC, Zanjani ED, Kersey JH (to be published) In vitro cytodestruction of leukemia cells in human bone marrow using a cocktail of monoclonal antibodies. In: Neth VR (ed) Modern trends in human leukemia.Google Scholar
  20. 20.
    Kaizer H, Levy R, Santos GW (1982) Autologous bone marrow transplantation in T-cell malignancies: Use of in vitro monoclonal antibody treatment of remission marrow to eliminate tumor cells. J Cell Biochem [Supp] 6: 41Google Scholar
  21. 21.
    Ritz J, Sallan S, Bast RC, Liptin JM, Clavell LA, Feeney M, Hercend T, Nathan DG, Schloss-man SF (1982) Autologous bone marrow transplantation in CALLA positive acute lymphoblastic leukemia after in vitro treatment with J5 monoclonal antibody and complement. Lancet 2: 60–63PubMedCrossRefGoogle Scholar
  22. 22.
    LeBien T, Kersey J (1980) A monoclonal antibody (TA-1) reactive with human T lymphocytes and monocytes. J Immunol 125: 2208–2214PubMedGoogle Scholar
  23. 23.
    LeBien TW, Boue DR, Bradley JG, Kersey JH (1982) Antibody affinity may influence antigenic modulation of the common acute lymphoblastic leukemia antigen in vitro. J Immunol 129: 2287–2292PubMedGoogle Scholar
  24. 24.
    Tatsumi E, Sugimoto T, Minato K, Sagawa K, Civen C, Early A, Preisler H, Henderson E, Minowada J (1982) Heterogeneity of AML and CML blasts as determined by multiple monoclonal antibodies. Proc Am Soc Cl in OncolGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1984

Authors and Affiliations

  • J. H. Kersey
  • T. W. LeBien

There are no affiliations available

Personalised recommendations